BioLife Solutions exec sells 97K BLFS shares

BioLife Solutions Chief Quality and Operations officer Karen A. Foster reported open-market sales of a total of 97,423 shares of common stock in two transactions, at weighted average prices of $20.15 and $20.00 per share across multiple trades.

Accepted by SEC EDGAR 03/09/2026 - 06:11 PM EDT Learn about SEC filing dates

Rhea-AI Filing Summary

BioLife Solutions Chief Quality and Operations officer Karen A. Foster reported open-market sales of a total of 97,423 shares of common stock in two transactions, at weighted average prices of $20.15 and $20.00 per share across multiple trades. After these sales, she directly owns 113,242 shares.

Insider Trade Summary

Net Seller: 97,423 shares

Net Sell 2 txns

Insider Foster Karen A.

Role Chief Quality and Operations

Sold 97,423 shs ($1.96M)

Share of Position Sold 46.2%

Type	Security	Shares	Price	Value
Sale	Common Stock	500	$20.00	$10K
Sale	Common Stock	96,923	$20.15	$1.95M

Holdings After Transaction: Common Stock — 113,242 shares (Direct)

Holdings Before and After: Common Stock, 210,665 to 113,242 shares (Direct)

Other Insiders: 5 other insiders reported open-market sales of this stock in the 30 days up to this filing.

Footnotes (2)

1. F1. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.00 to $20.46, inclusive. The reporting person undertakes to provide to the registrant, any security holder of the registrant, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
2. F2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.00 to $20.02, inclusive. The reporting person undertakes to provide to the registrant, any security holder of the registrant, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider stock transactions did BLFS executive Karen Foster report?

Karen A. Foster reported selling 97,423 shares of BioLife Solutions common stock in open-market transactions. The filing lists two sales at weighted average prices of $20.15 and $20.00 per share, executed across multiple trades within narrow price ranges.

At what prices were the BLFS shares sold in Karen Foster’s Form 4?

The Form 4 reports weighted average sale prices of $20.15 and $20.00 per BLFS share. Footnotes explain these shares were sold in multiple trades, with prices ranging from $20.00 to $20.46 and $20.00 to $20.02, respectively.

How many BLFS shares does Karen Foster own after the reported sales?

After the reported open-market sales, Karen A. Foster directly owns 113,242 shares of BioLife Solutions common stock. This figure in the Form 4 reflects her remaining direct ownership position immediately following the transactions disclosed in the filing.

What is Karen Foster’s role at BioLife Solutions (BLFS)?

Karen A. Foster is identified as an officer of BioLife Solutions with the title Chief Quality and Operations. Her Form 4 filing reflects transactions in the company’s common stock made in her capacity as a reporting insider under SEC rules.

Were Karen Foster’s BLFS stock sales single trades or multiple transactions?

The sales were executed as multiple transactions on each reported date. Footnotes state the prices are weighted averages and that individual trades occurred within specified price ranges, and detailed trade-by-trade information is available upon request to the company or regulators.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Foster Karen A.

(Last) (First) (Middle)

3303 MONTE VILLA PARKWAY

SUITE 310

(Street)

BOTHELL WA 98021

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
BIOLIFE SOLUTIONS INC [ BLFS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Quality and Operations

3. Date of Earliest Transaction (Month/Day/Year)
03/05/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/05/2026		S		96,923	D	$20.15(1)	113,742	D
Common Stock	03/09/2026		S		500	D	$20(2)	113,242	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.00 to $20.46, inclusive. The reporting person undertakes to provide to the registrant, any security holder of the registrant, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.00 to $20.02, inclusive. The reporting person undertakes to provide to the registrant, any security holder of the registrant, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

Remarks:

	/s/ Karen A. Foster	03/09/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.